EuroPCR Stent Wrap-Up: Biotronik’s Magmaris magnesium stent, Reva’s Fantom Polymer DES, and Elixir’s DESolve
This article was originally published in Clinica
Executive Summary
EuroPCR is one of the most important annual conferences for interventional cardiology in the world, always showcasing new catheter-based technologies. The clinical trial presentations at this year’s event, held May 17-20 in Paris, included long-term registry data evaluating established technologies, including Boston Scientific’s Promus Element everolimus-eluting stentand Synergy biosorbable everolimus-eluting stent. But this year’s meeting also included presentations of novel and unproven technologies, especially new approaches to biosorbable stents.
You may also be interested in...
OUS Approvals Analysis: Small Companies Dominate International Approvals In April
April was a return to a more typical volume of medical device approvals outside the US after a particularly busy March. And the big names in medtech were mostly quiet in April's OUS approvals, according to Medtech Insight's Approval Tracker.
Robert Byrne: Absorb, Synergy, And The Future Of Coronary Stents
One of the most controversial, and potentially impactful, questions in medical device development today is how to better prevent late events, especially late stent-thrombosis, in coronary stent patients. The two leading answers to this question are a completely bioresorbable drug-eluting stent and a metal drug-eluting stent with a bioresorbable polymer, but there may be even more ideas on the horizon. One of the leading experts in the field and a cardiologist with experience with most of these new technologies, Robert Byrne of Deutsches Herzzentrum in Munich, recently talked to Medtech Insight about the questions that still need to be answered in this field and how it can move forward.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.